Please login to the form below

Not currently logged in
Email:
Password:

Lamzede

This page shows the latest Lamzede news and features for those working in and with pharma, biotech and healthcare.

Chiesi launches new rare disease R&D division

Chiesi launches new rare disease R&D division

Chiesi already markets rare disease therapy Lamzede (velmanase alfa), which is approved by the European Medicines Agency for the treatment of patients with mild to moderate alpha-mannosidosis. ... Chiesi acquired Lamzede when it bought Zymenex in 2013

Latest news

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Collected Group

Collected Group is a forward thinking healthcare communication company that supports biopharma and diagnostic companies to engage in more lasting...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....